Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

PMI vs RCEL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RCEL Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–4 Matrix Metrics)

RCEL Overall Winner 6-Pillar Tally: PMI 1 – 4 RCEL (1 Tie) Matrix Metrics: PMI 4 – 6 RCEL

As of Nov 19, 2026, Avita Medical, Inc. (RCEL) is the stronger overall head-to-head candidate over Picard Medical, Inc. (PMI) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). PMI carries a Unified Composite Score of 48.4/100 (HOLD) at $6.30 (N/M Forward P/E, -248.1% operating margin), whereas RCEL carries 45.8/100 (HOLD) at $15.99 (10.3x Forward P/E, -33.9% operating margin).

  • Composite vs. Pillar Nuance: While PMI currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. RCEL 45.8/100 HOLD), RCEL captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-33.9% vs. -248.1% operating margin) and revenue trajectory (+53.1% vs. +38.6% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PMI vs RCEL
PMI NYSE American
Picard Medical, Inc.
Surgical & Medical Instruments & Apparatus
$6.30
-2.17% 1D
Market Cap $17.1M
TTM Revenue $6.3M
Forward P/E N/M
Beta / 30D Vol 54.06β · 134% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 39.0 Fund 45.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 42
RSI-14: 42.1 · SMA20: $7.55 · SMA50: $7.62
RCEL NASDAQ Head-to-Head Winner
Avita Medical, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$15.99
-4.99% 1D
Market Cap $533.3M
TTM Revenue $85M
Forward P/E 10.3x
Beta / 30D Vol 1.59β · 64% Vol
Unified Composite Score
45.8 / 100 HOLD
Tech 41.0 Fund 44.0 Flow 67.0 Mom 31.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (21.7% over 20 days), RSI 54
RSI-14: 54.0 · SMA20: $16.13 · SMA50: $13.84

6-Pillar Scorecard Institutional Category Breakdown (PMI 1 – 4 RCEL)

Columns: Metric · PMI · RCEL
1. Valuation Multiples PMI
Forward P/E N/M 10.3x
Trailing P/E 2.9x 10.3x
PEG Ratio N/M N/M
EV / Revenue 3.2x 6.7x
2. Growth & Scale RCEL
Revenue Growth (YoY) +38.6% +53.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $6.3M $85M
Market Cap $17.1M $533.3M
3. Profitability & Quality RCEL
Gross Margin 18.6% 82.4%
Operating Margin -248.1% -33.9%
Net Profit Margin 0.0% -42.6%
Return on Equity (ROE) 0.0% -1746.3%
4. Balance Sheet & Cash Flow RCEL
Cash Generation (TTM) -$17M -$20M
Cash Flow Margin N/A -23.6%
Net Cash / Leverage $3.2M Net Debt $37M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RCEL
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 134.5% (14th %ile)
Put/Call OI Skew N/A 0.11x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PMI (4) vs RCEL (6)
Institutional Metric PMI RCEL Criterion Row Edge
Market Capitalization
Scale
$17.1M $533.3M Larger Scale RCEL
Trailing P/E Ratio
Valuation
2.9x 10.3x Lower Multiple PMI
Forward P/E Ratio
Valuation
N/M 10.3x Lower Multiple RCEL
Revenue Growth (YoY)
Growth
+38.6% +53.1% Higher Growth RCEL
Operating Margin (TTM)
Profitability
-248.1% -33.9% Higher Margin RCEL
Net Profit Margin
Profitability
0.0% -42.6% Higher Margin PMI
Return on Equity (ROE)
Capital Efficiency
0.0% -1746.3% Higher ROE PMI
52-Week Range Position
Momentum
34% ($0–$18) 84% ($3–$18) Stronger Trend RCEL
Beta / 30D Volatility
Risk Regime
54.06β · 134% Vol 1.59β · 64% Vol Lower Realized Risk RCEL
Unified Institutional Score
Composite Signal
48.4 / 100 (HOLD) 45.8 / 100 (HOLD) Higher Composite PMI
Trailing 12M Revenue (USD)
Operating Scale
$6.3M $85M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
18.6% 82.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.2x EV/Rev N/M PEG · 6.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$17M ($3.2M Net Debt) -$20M ($37M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RCEL +39.16 pp
PMI: -34.58% · RCEL: +4.58%
3M Horizon PMI +37.31 pp
PMI: +96.26% · RCEL: +58.95%
6M Horizon PMI +3174.26 pp
PMI: +3439.33% · RCEL: +265.07%
1Y Horizon RCEL +156.78 pp
PMI: +148.03% · RCEL: +304.81%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period PMI Revenue RCEL Revenue PMI Op. Margin RCEL Op. Margin Margin Leader
FY2018 N/A $0M N/A -1489.9% RCEL
FY2019 N/A $10M N/A -466.4% RCEL
FY2020 N/A $10M N/A -299.2% RCEL
FY2021 N/A $30M N/A -90.8% RCEL
FY2022 N/A $30M N/A -79.9% RCEL
FY2023 N/A $50M N/A -85.1% RCEL
FY2024 $0M $60M -312.3% -88.1% RCEL
FY2025 $0M $70M -268.4% -59.4% RCEL

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PMI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PMI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RCEL CONSOLIDATION
16d in phase · OBV NEUTRAL
Current IV 134.5%
IV Percentile 14th %ile
Put/Call OI Skew 0.11x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact RCEL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PMI Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $17.1M market capitalization and -248.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
RCEL Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $533.3M market capitalization and -33.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PMI vs RCEL Key Questions & Quantitative Answers

As of Nov 19, 2026, Avita Medical, Inc. (RCEL) is the stronger overall head-to-head candidate over Picard Medical, Inc. (PMI) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). PMI carries a Unified Composite Score of 48.4/100 (HOLD) at $6.30 (N/M Forward P/E, -248.1% operating margin), whereas RCEL carries 45.8/100 (HOLD) at $15.99 (10.3x Forward P/E, -33.9% operating margin). Composite vs. Pillar Nuance: While PMI currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. RCEL 45.8/100 HOLD), RCEL captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-33.9% vs. -248.1% operating margin) and revenue trajectory (+53.1% vs. +38.6% YoY).

RCEL leads the Growth & Scale pillar: PMI posts +38.6% YoY revenue growth and +0.0% YoY earnings growth on $6.3M TTM revenue (18.6% gross margin, -248.1% operating margin), compared with RCEL at +53.1% YoY revenue growth and +0.0% YoY earnings growth on $85M TTM revenue (82.4% gross margin, -33.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), PMI cumulative revenue shifted N/A while RCEL shifted +600.0%. In operating R&D and SG&A reinvestment, PMI deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RCEL.

PMI screens cheaper on headline valuation multiples. PMI trades at N/M Forward P/E, 2.9x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (unreported FCF margin), whereas RCEL trades at 10.3x Forward P/E, 10.3x Trailing P/E, N/M PEG, and 6.7x EV/Revenue (-23.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PMI (0.0% ROE) versus RCEL (-1746.3% ROE) capital efficiency.

In options market volatility and institutional positioning, PMI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (54.06β · 134% Vol realized risk). By comparison, RCEL carries 134.5% implied volatility (14th %ile, Compressed (<25th %ile)), a 0.11x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.59β · 64% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.